Open AccessClinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon‐like peptide‐1 receptor agonists
Author(s) -
Shiomi Megumi,
Takada Tesshu,
Tanaka Yoichi,
Yajima Keiko,
Isomoto Akira,
Sakamoto Masaki,
Otori Katsuya
Publication year - 2019
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.12900
Subject(s) - nausea , vomiting , medicine , gastroenterology , adverse effect , type 2 diabetes , diabetes mellitus , discontinuation , endocrinology
Aims/Introduction Research has proved a correlation between glucagon‐like peptide‐1 receptor agonists ( GLP ‐1 RA s) and gastrointestinal adverse events. Predominantly, nausea and vomiting are frequent gastrointestinal adverse events that lead to the discontinuation of GLP ‐1 RA s treatment. The present study aims to investigate clinical factors related to nausea and vomiting, considering diabetic complications and agents affecting the gastrointestinal tract, such as proton pump inhibitors ( PPI s) and histamine‐2 receptor antagonists (H2 RA s), in patients with type 2 diabetes treated with GLP ‐1 RA s. Materials and Methods This retrospective study included Japanese patients with type 2 diabetes who started receiving GLP ‐1 RA s therapy. We assessed nausea and vomiting up to 48 weeks after treatment with GLP ‐1 RA s and used Fine–Gray's proportional hazards model to investigate clinical factors related to nausea and vomiting. Results A total of 130 patients were included in this study. Patients with PPI s or H2 RA s showed a higher incidence of nausea and vomiting at 48 weeks than those without PPI s or H2 RA s. The multivariate analysis revealed that female sex, retinopathy and treatment with PPI s or H2 RA s were statistically significant risk factors for nausea and vomiting. Analysis of patients without PPI s or H2 RA s showed that female sex and retinopathy were also statistically significant risk factors. Conclusions The present study showed a significant correlation of PPI s or H2 RA s, female sex, and diabetic retinopathy with nausea and vomiting in patients with type 2 diabetes treated with GLP ‐1 RA s. Hence, the occurrence of nausea and vomiting in patients with these factors warrants attention.